Advanced Cancer Clinical Trial
— SHAPEOfficial title:
Survival Expectations and Hope Among Cancer Patients at End-of-Life
Verified date | July 2020 |
Source | Duke-NUS Graduate Medical School |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Literature shows that less than half of advanced cancer patients accurately understand their
prognosis, with most being overly optimistic. Investigators suspect that many patients are
reporting not what they believe, but what they would like to believe. This study aims to
discern patient's beliefs about prognosis independent of hope, to identify factors that
influence patient's beliefs, and to explore patient preferences for prognostic information.
Investigators propose to randomize 200 cancer patients with a prognosis of less than one year
to receive one of the two versions of a survey. Investigators hypothesize that, although many
patients will continue to be overly optimistic about their prognosis, those patients
responding to Version 2, followed by Version 1, will provide more accurate estimates.
Efforts to improve decision making require an understanding of patients' beliefs and
preferences for receiving prognostic information and identifying strategies to clearly convey
that information. This study will fill that gap.
Status | Active, not recruiting |
Enrollment | 200 |
Est. completion date | August 31, 2021 |
Est. primary completion date | August 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - The inclusion criteria for patients are: - Age = 21 years old - Singaporean/Singapore Permanent Resident (PR) - Diagnosed with advanced cancer by the primary physician - Prognosis of = 1 year as determined by the primary treating oncologist responding "YES" to the question "Do you believe that there is a high chance (greater than 50%) that this patient is unlikely to be alive in 12 months?" Only patients for whom the physicians respond as "YES" will be approached to participate in the study Exclusion Criteria: - Patients deemed to be mentally incompetent and those not aware of their diagnosis. |
Country | Name | City | State |
---|---|---|---|
Singapore | National Cancer Centre Singapore | Singapore | |
Singapore | Singapore General Hospital | Singapore |
Lead Sponsor | Collaborator |
---|---|
Duke-NUS Graduate Medical School | National Cancer Centre, Singapore, National University Hospital, Singapore |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of patients who knew they can not be cured | The primary aim of this study is to attempt to discern patient's beliefs about their prognosis independent of hope. We propose to address this aim by randomizing 200 Stage IV cancer patients with a prognosis of less than a year to receive one of the two sets of a carefully designed and pilot tested survey. Set A includes prognosis questions similar to those used in prior studies. Set B is identical to Set A but incorporates an incentive compatible strategy where a reward is offered for 'correct' answers, as determined by their treating physician's prediction. The incentive compatible approach has been shown to increase the accuracy of responses in a wide range of domains, including mortality risk predictions. We hypothesize that, although many patients will continue to convey an overly optimistic assessment of their prognosis, those patients responding to Set B followed by Set A, will provide more accurate estimates. | Baseline | |
Secondary | The percentage of patients who received the information the way they would have liked | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 |